Skyrizi

(risankizumab) Abbvie

Composition:

Skyrizi solution for injection in pre-filled pen 150mg/1ml

• Each pre-filled pen contains 150 mg risankizumab in 1 mL solution.

Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody selective to the interleukin (IL)-23 protein produced in Chinese Hamster Ovary cells using recombinant DNA technology.

Indications:

Plaque Psoriasis

• Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Psoriatic Arthritis

• Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).